Viking Therapeutics, INC 10-Q quarterly reports

Viking Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026, detailing financial performance, ongoing clinical trials, and strategic updates.

Viking Therapeutics, Inc. reported its first quarter 2026 financial results, highlighting significant increases in research and development expenses and a substantial cash balance.

Viking Therapeutics reported significantly increased R&D expenses and net losses in Q3 2025, driven by the advancement of its VK2735 programs into Phase 3 and positive Phase 2 oral results, while maintaining a strong cash position.

Viking Therapeutics reported significant progress in its clinical pipeline, initiating Phase 3 trials for its obesity drug VK2735 and revealing positive 52-week histologic data for its NASH candidate VK2809, alongside increased R&D expenses and a strong cash position.

Viking Therapeutics reports its financial results for the first quarter of 2025, emphasizing ongoing clinical trials and strategic manufacturing agreements.

Viking Therapeutics' third quarter 2024 report details increased R&D spending, a net loss, and a strong cash position to fund operations through at least 2025.

Viking Therapeutics' second quarter 2024 financial results show increased research and development spending and a significant rise in cash and short-term investments.

Viking Therapeutics' strategic financial maneuvers and promising clinical developments in metabolic disorder treatments position the company for a robust 2024.